Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

In the Media

  • June 16, 2021

IntegraSyn™ – a flexible, high yield and cost-effective cannabinoid manufacturing system

InMed’s scientific team has developed IntegraSyn™ – a flexible, high yield and cost-effective manufacturing system to produce pharmaceutical-grade, bio-identical cannabinoids. InMed recently announced that IntegraSyn™ has achieved a cannabinoid yield of 5 g/L, a commercially viable yield that significantly exceeds currently reported industry yields.

How does IntegraSyn™ work?

  • IntegraSyn™ integrates well-established manufacturing processes such as biosynthesis, biotransformation and other traditional pharmaceutical manufacturing methods.
  • IntegraSyn™ optimizes use of expensive manufacturing steps, using sophisticated, but cost efficient starting materials.
  • IntegraSyn™ allows for flexibly shifting from production of one cannabinoid to a range of others, providing improved yields.
  • And IntegraSyn™ is designed to be scalable and to produce the consistent, compliant, highly pure cannabinoids required for pharmaceutical products.

As interest in the therapeutic potential of cannabinoids continues to grow, IntegraSyn™ may be the solution to provide access to a range of cost-effective, bio-identical cannabinoids.

Full Article
Source: BTV

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Latest Articles

Why explore cannabinoids as potential therapeutic targets for neurodegenerative diseases?

In this video, Eric A. Adams explains how the body’s endocannabinoid system has natural cannabinoid receptors throughout the body that interact with cannabinoids and are

Read More
February 1, 2023

The Dales Report: InMed Pharmaceuticals Clinical Trial Program Moving Forward In 2023

InMed’s CEO, Eric A. Adams, joins The Dales Report webcast to talk about the 2023 plans for the company’s rare cannabinoid programs in epidermolysis bullosa

Read More
January 24, 2023

The Dales Report: InMed Focused On Clinical Trial Success In 2023

The Dales Report’s Shadd Dales interviews InMed CEO, Eric A. Adams, to talk about the company’s upcoming pharmaceutical development plans for 2023. Eric speaks about

Read More
December 28, 2022
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent